Objective To mine the adverse events (ADE) data of anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) on the base of the United States Food and Drug Administration (FDA) adverse event reporting system (FAERS) database, so as to provide the basis for clinical safe use of drugs.Methods ADE data of five ALK-TKIs (the first generation of crizotinib, the second generation of ceritinib, brigatinib, alectinib, and the third generation of lorlatinib) in 14 quarters from the first quarter of 2019 to the second quarter of 2022 were extracted from FAERS database. After deduplication and data cleaning, signal mining was performed using reporting odds ratio (ROR) and proportional reporting ratio (PRR).Results A total of 8 444 ADE reports with five ALK-TKIs as the primary suspected drugs were screened out, and 563 ADE signals were obtained after analysis and processing. After removing the irrelevant signals such as product problems, social environment, various injuries, poisoning, and operation complications as well as various operations and medical treatments, a total of 20 kinds of system/organ class (SOC) were affected.Conclusion The SOCs involved by the five ALK-TKIs varied greatly, so special attention should be paid to the monitoring of systemic diseases when these drugs used clinically. The common ADE signals obtained in this study were consistent with the specifications to a certain extent, proving the reliability of the research method. The clinical use of the five ALK-TKIs should be individualized considering the characteristics of different drugs.